Petr Vachal

This inventor holds 16 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 16 EPO patents, primarily in Cholesterol Transfer Protein Inhibitors. Top assignees: Merck Sharp + Dohme Corp., Merck + Co., Inc.. Active years: 2009-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Petr Vachal. Retrieved from https://idiyas.com/inventor/petr-vachal

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 16 (Patent Applications = 5)

% Patents Active = 93.8

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 16 (Patent Applications = 16)

Average Co-Inventor Count = 5.1

ph-index = 4

Forward Citations = 69(Granted Patents)

Company Filing History:

15 out of 2,405

Merck Sharp + Dohme Corp.

Years Active: 2009-2019

Loading Chart...

Areas of Expertise:

CETP Inhibitors

Antiviral Compounds

Phosphoramide

Isoxazolines

Bicyclic Ureas

Beta-Amino Acids

Spirocyclic Compounds

Oxazolidinones

Heterocycles

Benzopiperazines

Triazaspiro Compounds

S1P Receptor Agonists

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10450335 - Antiviral oxime phosphoramide compounds (2019-10-22),

2. 10011572 - Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein (2018-07-03),

3. 9981970 - Bicyclic ureas and thiadiazolidine-1, 1-dioxides as CETP inhibitors (2018-05-29),

4. 9822138 - Antiviral beta-amino acid ester phosphodiamide compounds (2017-11-21),

5. 9717714 - Spirocyclic CETP inhibitors (2017-08-01),

6. 9688630 - 3,3'-disubstituted indolines as inhibitors of cholesterol ester transfer protein (2017-06-27),

7. 9663534 - Fused bicyclic isoxazolines as inhibitors of cholesterol ester transfer protein (2017-05-30),

8. 9353101 - Cyclic amine substituted heterocyclic CETP inhibitors (2016-05-31),

9. 9346825 - Fused bicyclic oxazolidinone CETP inhibitor (2016-05-24),

10. 9221834 - Cyclic amine substituted oxazolidinone CETP inhibitor (2015-12-29),

11. 9126976 - Substituted benzopiperazines as CETP inhibitors (2015-09-08),

12. 8921555 - Substituted-1,3,8-triazaspiro[4.5]decane-2,4-diones (2014-12-30),

13. 8871738 - Fused bicyclic oxazolidinone CETP inhibitor (2014-10-28),

14. 8492398 - Spiroazaindoles (2013-07-23),

15. 8309544 - Spiroindalones (2012-11-13),

Title: Petr Vachal: Pioneering Innovator in Biomedical Chemistry

Introduction:

Petr Vachal, a renowned inventor based in Summit, NJ (US), has left an indelible mark in the field of biomedical chemistry with his groundbreaking patents and innovative research. With an impressive portfolio of 16 patents, Vachal's contributions to pharmaceutical advancements have significantly impacted the healthcare industry.

Latest Patents:

Vachal's latest patents include the development of Antiviral oxime phosphoramide compounds and Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein. These compounds have shown promising results in inhibiting HIV reverse transcriptase and treating or preventing atherosclerosis, showcasing Vachal's commitment to creating impactful solutions for complex medical challenges.

Career Highlights:

Throughout his career, Vachal has worked with esteemed companies such as Merck Sharp & Dohme Corporation and Merck & Company, Inc., where he has played a pivotal role in driving research and development efforts. His expertise in medicinal chemistry has led to the successful development of novel pharmaceutical compounds with significant therapeutic potential.

Collaborations:

Vachal's collaborative efforts with fellow researchers such as Pengcheng Patrick Shao and Feng Ye have further amplified the impact of his work. By combining their expertise and insights, Vachal and his colleagues have pushed the boundaries of scientific discovery, leading to the creation of innovative solutions that address critical medical needs.

Conclusion:

In conclusion, Petr Vachal's relentless pursuit of innovation and his steadfast dedication to advancing biomedical chemistry have established him as a trailblazer in the field. His contributions to the development of novel pharmaceutical compounds underscore his commitment to improving global healthcare outcomes, making him a significant figure in the realm of patentable inventions.

Profile summary based on public USPTO records.